Role of transporters in the distribution of platinum-based drugs

Frontiers in Pharmacology

Volumn 6, Issue APR, 2015, Pages

  Harrach, Saliha ^a   Ciarimboli, Giuliano ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

Cisplatin; Oxaliplatin; Side effects; Transporters; Uptake

Indexed keywords

CARRIER PROTEIN; CISPLATIN; COPPER TRANSPORTER 1; COPPER TRANSPORTER 2; MENKES PROTEIN; MULTIDRUG AND TOXIN EXTRUSION PROTEIN 1; ORGANIC CATION TRANSPORTER 1; ORGANIC CATION TRANSPORTER 2; ORGANIC CATION TRANSPORTER 3; UNCLASSIFIED DRUG; WILSON DISEASE PROTEIN;

CANCER CHEMOTHERAPY; DRUG DISTRIBUTION; DRUG TRANSPORT; HUMAN; KIDNEY PROXIMAL TUBULE; KIDNEY TUBULE CELL; NEPHROTOXICITY; NEUROTOXICITY; NONHUMAN; OTOTOXICITY; PROTEIN EXPRESSION; SHORT SURVEY;

EID: 84930622243     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2015.00085     Document Type: Short Survey

References (93)

1. Adelsberger, H., Quasthoff, S., Grosskreutz, J., Lepier, A., Eckel, F., and Lersch, C. (2000). The chemotherapeutic oxaliplatin alters voltage-gated Na(+) channel kinetics on rat sensory neurons. Eur. J. Pharmacol. 406, 25-32. doi: 10.1016/S0014-2999(00)00667-1.
2. Albers, J. W., Chaudhry, V., Cavaletti, G., and Donehower, R. C. (2011). Interventions for preventing neuropathy caused by cisplatin and related compounds. Cochrane Database Syst. Rev. 2:CD005228. doi: 10.1002/14651858.CD005228.pub3.
3. Amptoulach, S., and Tsavaris, N. (2011). Neurotoxicity caused by the treatment with platinum analogues. Chemother. Res. Pract. 2011:843019. doi: 10.1155/2011/843019.
4. Blair, B. G., Larson, C. A., Adams, P. L., Abada, P. B., Pesce, C. E., Safaei, R., et al. (2011). Copper transporter 2 regulates endocytosis and controls tumor growth and sensitivity to cisplatin in vivo. Mol. Pharmacol. 79, 157-166. doi: 10.1124/mol.110.068411.
5. Blair, B. G., Larson, C. A., Safaei, R., and Howell, S. B. (2009). Copper transporter 2 regulates the cellular accumulation and cytotoxicity of Cisplatin and Carboplatin. Clin. Cancer Res. 15, 4312-4321. doi: 10.1158/1078-0432.CCR-09-0311.
6. Bregman, C. L., and Williams, P. D. (1986). Comparative nephrotoxicity of carboplatin and cisplatin in combination with tobramycin. Cancer Chemother. Pharmacol. 18, 117-123. doi: 10.1007/BF00262279.
7. Cano, J. R., Catalan, B., and Jara, C. (1998). [Neuronopathy due to cisplatin]. Rev. Neurol. 27, 606-610.
8. Carozzi, V. A., Marmiroli, P., and Cavaletti, G. (2010). The role of oxidative stress and anti-oxidant treatment in platinum-induced peripheral neurotoxicity. Curr. Cancer Drug Targets 10, 670-682. doi: 10.2174/156800910793605820.
9. Cassidy, J., and Misset, J. L. (2002). Oxaliplatin-related side effects: characteristics and management. Semin. Oncol. 29, 11-20. doi: 10.1053/sonc.2002.35524.
10. Cavaletti, G., and Zanna, C. (2002). Current status and future prospects for the treatment of chemotherapy-induced peripheral neurotoxicity. Eur. J. Cancer 38, 1832-1837. doi: 10.1016/S0959-8049(02)00229-0.
11. Chen, L., Hong, C., Chen, E. C., Yee, S. W., Xu, L., Almof, E. U., et al. (2013). Genetic and epigenetic regulation of the organic cation transporter 3, SLC22A3. Pharmacogenomics J. 13, 110-120. doi: 10.1038/tpj.2011.60.
12. Ciarimboli, G. (2008). Organic cation transporters. Xenobiotica 38, 936-971. doi: 10.1080/00498250701882482.
13. Ciarimboli, G. (2011). Role of organic cation transporters in drug-induced toxicity. Expert Opin. Drug Metab. Toxicol. 7, 159-174. doi: 10.1517/17425255.2011.547474.
14. Ciarimboli, G., Deuster, D., Knief, A., Sperling, M., Holtkamp, M., Edemir, B., et al. (2010). Organic cation transporter 2 mediates cisplatin-induced oto-and nephrotoxicity and is a target for protective interventions. Am. J. Pathol. 176, 1169-1180. doi: 10.2353/ajpath.2010.090610.
15. Ciarimboli, G., Ludwig, T., Lang, D., Pavenstädt, H., Koepsell, H., Piechota, H. J., et al. (2005). Cisplatin nephrotoxicity is critically mediated via the human organic cation transporter 2. Am. J. Pathol. 167, 1477-1484. doi: 10.1016/S0002-9440(10)61234-5.
16. Ciarimboli, G., and Schlatter, E. (2005). Regulation of organic cation transport. Pflugers Arch. 449, 423-441. doi: 10.1007/s00424-004-1355-5.
17. Daugaard, G. (1990). Cisplatin nephrotoxicity: experimental and clinical studies. Dan. Med. Bull. 37, 1-12.
18. Dobyan, D. C., Levi, J., Jacobs, C., Kosek, J., and Weiner, M. W. (1980). Mechanism of cis-platinum nephrotoxicity: II. Morphologic observations. J. Pharmacol. Exp. Ther. 213, 551-556.
19. Einhorn, L. H. (2002). Curing metastatic testicular cancer. Proc. Natl. Acad. Sci. U.S.A. 99, 4592-4595. doi: 10.1073/pnas.072067999.
20. Filipski, K. K., Loos, W. J., Verweij, J., and Sparreboom, A. (2008). Interaction of Cisplatin with the human organic cation transporter 2. Clin. Cancer Res. 14, 3875-3880. doi: 10.1158/1078-0432.CCR-07-4793.
21. Filipski, K. K., Mathijssen, R. H., Mikkelsen, T. S., Schinkel, A. H., and Sparreboom, A. (2009). Contribution of organic cation transporter 2 (OCT2) to cisplatin-induced nephrotoxicity. Clin. Pharmacol. Ther. 86, 396-402. doi: 10.1038/clpt.2009.139.
22. Gamelin, E., Gamelin, L., Bossi, L., and Quasthoff, S. (2002). Clinical aspects and molecular basis of oxaliplatin neurotoxicity: current management and development of preventive measures. Semin. Oncol. 29, 21-33. doi: 10.1053/sonc.2002.35525.
23. Goren, M. P., Wright, R. K., and Horowitz, M. E. (1986). Cumulative renal tubular damage associated with cisplatin nephrotoxicity. Cancer Chemother. Pharmacol. 18, 69-73. doi: 10.1007/BF00253068.
24. Gupta, A., and Lutsenko, S. (2009). Human copper transporters: mechanism, role in human diseases and therapeutic potential. Future Med. Chem. 1, 1125-1142. doi: 10.4155/fmc.09.84.
25. Hartmann, J. T., and Lipp, H. P. (2003). Toxicity of platinum compounds. Expert Opin. Pharmacother. 4, 889-901. doi: 10.1517/14656566.4.6.889.
26. Hellberg, V., Wallin, I., Eriksson, S., Hernlund, E., Jerremalm, E., Berndtsson, M., et al. (2009). Cisplatin and oxaliplatin toxicity: importance of cochlear kinetics as a determinant for ototoxicity. J. Natl. Cancer Inst. 101, 37-47. doi: 10.1093/jnci/djn418.
27. Holzer, A. K., Manorek, G. H., and Howell, S. B. (2006). Contribution of the major copper influx transporter CTR1 to the cellular accumulation of cisplatin, carboplatin, and oxaliplatin. Mol. Pharmacol. 70, 1390-1394. doi: 10.1124/mol.106.022624.
28. Holzer, A. K., Samimi, G., Katano, K., Naerdemann, W., Lin, X., Safaei, R., et al. (2004). The copper influx transporter human copper transport protein 1 regulates the uptake of cisplatin in human ovarian carcinoma cells. Mol. Pharmacol. 66, 817-823. doi: 10.1124/mol.104.001198.
29. Houjou, T., Nakano, K., Ike, O., Wada, H., Hitomi, S., Shinmi, Y., et al. (1996). Oral sustained-release cisplatin capsule. J. Pharm. Pharmacol. 48, 474-478. doi: 10.1111/j.2042-7158.1996.tb05957.x.
30. Ip, V., Liu, J. J., Mercer, J. F., and McKeage, M. J. (2010). Differential expression of ATP7A, ATP7B and CTR1 in adult rat dorsal root ganglion tissue. Mol. Pain 6, 53. doi: 10.1186/1744-8069-6-53.
31. Ishida, S., Lee, J., Thiele, D. J., and Herskowitz, I. (2002). Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals. Proc. Natl. Acad. Sci. U.S.A. 99, 14298-14302. doi: 10.1073/pnas.162491399.
32. Jacobs, C., Coleman, C. N., Rich, L., Hirst, K., and Weiner, M. W. (1984). Inhibition of cis-diamminedichloroplatinum secretion by the human kidney with probenecid. Cancer Res. 44, 3632-3635.
33. Jong, N. N., Nakanishi, T., Liu, J. J., Tamai, I., and McKeage, M. J. (2011). Oxaliplatin transport mediated by organic cation/carnitine transporters OCTN1 and OCTN2 in overexpressing human embryonic kidney 293 cells and rat dorsal root ganglion neurons. J. Pharmacol. Exp. Ther. 338, 537-547. doi: 10.1124/jpet.111.181297.
34. Katano, K., Safaei, R., Samimi, G., Holzer, A., Rochdi, M., and Howell, S. B. (2003). The copper export pump ATP7B modulates the cellular pharmacology of carboplatin in ovarian carcinoma cells. Mol. Pharmacol. 64, 466-473. doi: 10.1124/mol.64.2.466.
35. Katano, K., Safaei, R., Samimi, G., Holzer, A., Tomioka, M., Goodman, M., et al. (2004). Confocal microscopic analysis of the interaction between cisplatin and the copper transporter ATP7B in human ovarian carcinoma cells. Clin. Cancer Res. 10, 4578-4588. doi: 10.1158/1078-0432.CCR-03-0689.
36. Katsuda, H., Yamashita, M., Katsura, H., Yu, J., Waki, Y., Nagata, N., et al. (2010). Protecting Cisplatin-induced nephrotoxicity with cimetidine does not affect antitumor activity. Biol. Pharm. Bull. 33, 1867-1871. doi: 10.1248/bpb.33.1867.
37. Koepsell, H. (2004). Polyspecific organic cation transporters: their functions and interactions with drugs. Trends Pharmacol. Sci. 25, 375-381. doi: 10.1016/j.tips.2004.05.005.
38. Komatsu, M., Sumizawa, T., Mutoh, M., Chen, Z. S., Terada, K., Furukawa, T., et al. (2000). Copper-transporting P-type adenosine triphosphatase (ATP7B) is associated with cisplatin resistance. Cancer Res. 60, 1312-1316.
39. Lanvers-Kaminsky, C., Sprowl, J. A., Malath, I., Deuster, D., Eveslage, M., Schlatter, E., et al. (2015). Human organic cation transporter 2 variant c.808G>T carriers are protected against Cisplatin-induced ototoxicity. Pharmacogenomics 16, 323-332. doi: 10.2217/pgs.14.182.
40. Larson, C. A., Blair, B. G., Safaei, R., and Howell, S. B. (2009). The role of the mammalian copper transporter 1 in the cellular accumulation of platinum-based drugs. Mol. Pharmacol. 75, 324-330. doi: 10.1124/mol.108.052381.
41. Lee, Y. Y., Choi, C. H., Do, I. G., Song, S. Y., Lee, W., Park, H. S., et al. (2011). Prognostic value of the copper transporters, CTR1 and CTR2, in patients with ovarian carcinoma receiving platinum-based chemotherapy. Gynecol. Oncol. 122, 361-365. doi: 10.1016/j.ygyno.2011.04.025.
42. Li, Q., Guo, D., Dong, Z., Zhang, W., Zhang, L., Huang, S. M., et al. (2013). Ondansetron can enhance cisplatin-induced nephrotoxicity via inhibition of multiple toxin and extrusion proteins (MATEs). Toxicol. Appl. Pharmacol. 273, 100-109. doi: 10.1016/j.taap.2013.08.024.
43. Liang, Z. D., Long, Y., Tsai, W. B., Fu, S., Kurzrock, R., Gagea-Iurascu, M., et al. (2012). Mechanistic basis for overcoming platinum resistance using copper chelating agents. Mol. Cancer Ther. 11, 2483-2494. doi: 10.1158/1535-7163.MCT-12-0580.
44. Liang, Z. D., Stockton, D., Savaraj, N., and Tien, K. M. (2009). Mechanistic comparison of human high-affinity copper transporter 1-mediated transport between copper ion and cisplatin. Mol. Pharmacol. 76, 843-853. doi: 10.1124/mol.109.056416.
45. Lin, X., Okuda, T., Holzer, A., and Howell, S. B. (2002). The copper transporter CTR1 regulates cisplatin uptake in Saccharomyces cerevisiae. Mol. Pharmacol. 62, 1154-1159. doi: 10.1124/mol.62.5.1154.
46. Liu, J. J., Jamieson, S. M., Subramaniam, J., Ip, V., Jong, N. N., Mercer, J. F., et al. (2009). Neuronal expression of copper transporter 1 in rat dorsal root ganglia: association with platinum neurotoxicity. Cancer Chemother. Pharmacol. 64, 847-856. doi: 10.1007/s00280-009-1017-6.
47. Lutsenko, S., Barnes, N. L., Bartee, M. Y., and Dmitriev, O. Y. (2007). Function and regulation of human copper-transporting ATPases. Physiol. Rev. 87, 1011-1046. doi: 10.1152/physrev.00004.2006.
48. Mangala, L. S., Zuzel, V., Schmandt, R., Leshane, E. S., Halder, J. B., Armaiz-Pena, G. N., et al. (2009). Therapeutic targeting of ATP7B in ovarian carcinoma. Clin. Cancer Res. 15, 3770-3780. doi: 10.1158/1078-0432.CCR-08-2306.
49. Martinez-Balibrea, E., Martinez-Cardus, A., Musulen, E., Gines, A., Manzano, J. L., Aranda, E., et al. (2009). Increased levels of copper efflux transporter ATP7B are associated with poor outcome in colorectal cancer patients receiving oxaliplatin-based chemotherapy. Int. J. Cancer 124, 2905-2910. doi: 10.1002/ijc.24273.
50. Matsushima, S., Maeda, K., Inoue, K., Ohta, K. Y., Yuasa, H., Kondo, T., et al. (2009). The inhibition of human multidrug and toxin extrusion 1 is involved in the drug-drug interaction caused by cimetidine. Drug Metab. Dispos. 37, 555-559. doi: 10.1124/dmd.108.023911.
51. Meijer, C., de Vries, E. G., Marmiroli, P., Tredici, G., Frattola, L., and Cavaletti, G. (1999). Cisplatin-induced DNA-platination in experimental dorsal root ganglia neuronopathy. Neurotoxicology 20, 883-887.
52. More, S. S., Li, S., Yee, S. W., Chen, L., Xu, Z., Jablons, D. M., et al. (2010). Organic cation transporters modulate the uptake and cytotoxicity of picoplatin, a third-generation platinum analogue. Mol. Cancer Ther. 9, 1058-1069. doi: 10.1158/1535-7163.MCT-09-1084.
53. Musial-Bright, L., Fengler, R., Henze, G., and Hernaiz, D. P. (2011). Carboplatin and ototoxicity: hearing loss rates among survivors of childhood medulloblastoma. Childs Nerv. Syst. 27, 407-413. doi: 10.1007/s00381-010-1300-1.
54. Nakagawa, T., Inoue, Y., Kodama, H., Yamazaki, H., Kawai, K., Suemizu, H., et al. (2008). Expression of copper-transporting P-type adenosine triphosphatase (ATP7B) correlates with cisplatin resistance in human non-small cell lung cancer xenografts. Oncol. Rep. 20, 265-270. doi: 10.3892/or_00000002.
55. Nakamura, T., Yonezawa, A., Hashimoto, S., Katsura, T., and Inui, K. I. (2010). Disruption of multidrug and toxin extrusion MATE1 potentiates cisplatin-induced nephrotoxicity. Biochem. Pharmacol. 80, 1762-1767. doi: 10.1016/j.bcp.2010.08.019.
56. Ohrvik, H., Nose, Y., Wood, L. K., Kim, B. E., Gleber, S. C., Ralle, M., et al. (2013). Ctr2 regulates biogenesis of a cleaved form of mammalian Ctr1 metal transporter lacking the copper-and cisplatin-binding ecto-domain. Proc. Natl. Acad. Sci. U.S.A. 110, E4279-E4288. doi: 10.1073/pnas.1311749110.
57. Ohrvik, H., and Thiele, D. J. (2014). The role of Ctr1 and Ctr2 in mammalian copper homeostasis and platinum-based chemotherapy. J. Trace Elem. Med. Biol. doi: 10.1016/j.jtemb.2014.03.006. [Epub ahead of print].
58. Pabla, N., and Dong, Z. (2008). Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney Int. 73, 994-1007. doi: 10.1038/sj.ki.5002786.
59. Price, P. M., Safirstein, R. L., and Megyesi, J. (2004). Protection of renal cells from cisplatin toxicity by cell cycle inhibitors. Am. J. Physiol. Renal Physiol. 286, F378-F384. doi: 10.1152/ajprenal.00192.2003.
60. Rabik, C. A., and Dolan, M. E. (2007). Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat. Rev. 33, 9-23. doi: 10.1016/j.ctrv.2006.09.006.
61. Reddel, R. R., Kefford, R. F., Grant, J. M., Coates, A. S., Fox, R. M., and Tattersall, M. H. (1982). Ototoxicity in patients receiving cisplatin: importance of dose and method of drug administration. Cancer Treat. Rep. 66, 19-23.
62. Renes, J., de Vries, E. G., Jansen, P. L., and Muller, M. (2000). The (patho)physiological functions of the MRP family. Drug Resist. Updat. 3, 289-302. doi: 10.1054/drup.2000.0156.
63. Roelofs, R. I., Hrushesky, W., Rogin, J., and Rosenberg, L. (1984). Peripheral sensory neuropathy and cisplatin chemotherapy. Neurology 34, 934-938. doi: 10.1212/WNL.34.7.934.
64. Rybak, L. P., and Ramkumar, V. (2007). Ototoxicity. Kidney Int. 72, 931-935. doi: 10.1038/sj.ki.5002434.
65. Safaei, R., Adams, P. L., Maktabi, M. H., Mathews, R. A., and Howell, S. B. (2012). The CXXC motifs in the metal binding domains are required for ATP7B to mediate resistance to cisplatin. J. Inorg. Biochem. 110, 8-17. doi: 10.1016/j.jinorgbio.2012.02.016.
66. Safaei, R., and Howell, S. B. (2005). Copper transporters regulate the cellular pharmacology and sensitivity to Pt drugs. Crit. Rev. Oncol. Hematol. 53, 13-23. doi: 10.1016/j.critrevonc.2004.09.007.
67. Safaei, R., Otani, S., Larson, B. J., Rasmussen, M. L., and Howell, S. B. (2008). Transport of cisplatin by the copper efflux transporter ATP7B. Mol. Pharmacol. 73, 461-468. doi: 10.1124/mol.107.040980.
68. Samimi, G., Katano, K., Holzer, A. K., Safaei, R., and Howell, S. B. (2004b). Modulation of the cellular pharmacology of cisplatin and its analogs by the copper exporters ATP7A and ATP7B. Mol. Pharmacol. 66, 25-32. doi: 10.1124/mol.66.1.25.
69. Samimi, G., Safaei, R., Katano, K., Holzer, A. K., Rochdi, M., Tomioka, M., et al. (2004a). Increased expression of the copper efflux transporter ATP7A mediates resistance to cisplatin, carboplatin, and oxaliplatin in ovarian cancer cells. Clin. Cancer Res. 10, 4661-4669. doi: 10.1158/1078-0432.CCR-04-0137.
70. Schaeffeler, E., Hellerbrand, C., Nies, A. T., Winter, S., Kruck, S., Hofmann, U., et al. (2011). DNA methylation is associated with downregulation of the organic cation transporter OCT1 (SLC22A1) in human hepatocellular carcinoma. Genome Med. 3, 82. doi: 10.1186/gm298.
71. Schlatter, E., Klassen, P., Massmann, V., Holle, S. K., Guckel, D., Edemir, B., et al. (2014). Mouse organic cation transporter 1 determines properties and regulation of basolateral organic cation transport in renal proximal tubules. Pflugers Arch. 466, 1581-1589. doi: 10.1007/s00424-013-1395-9.
72. Screnci, D., and McKeage, M. J. (1999). Platinum neurotoxicity: clinical profiles, experimental models and neuroprotective approaches. J. Inorg. Biochem. 77, 105-110. doi: 10.1016/S0162-0134(99)00135-X.
73. Sinani, D., Adle, D. J., Kim, H., and Lee, J. (2007). Distinct mechanisms for Ctr1-mediated copper and cisplatin transport. J. Biol. Chem. 282, 26775-26785. doi: 10.1074/jbc.M703973200.
74. Skinner, R. (2004). Best practice in assessing ototoxicity in children with cancer. Eur. J. Cancer 40, 2352-2354. doi: 10.1016/j.ejca.2004.08.002.
75. Sleijfer, D. T., Offerman, J. J., Mulder, N. H., Verweij, M., van der Hem, G. K., Schraffordt Koops, H. S., et al. (1987). The protective potential of the combination of verapamil and cimetidine on cisplatin-induced nephrotoxicity in man. Cancer 60, 2823-2828.
76. Sprowl, J. A., Ciarimboli, G., Lancaster, C. S., Giovinazzo, H., Gibson, A. A., Du, G., et al. (2013). Oxaliplatin-induced neurotoxicity is dependent on the organic cation transporter OCT2. Proc. Natl. Acad. Sci. U.S.A. 110, 11199-11204. doi: 10.1073/pnas.1305321110.
77. Takeshita, M., Banno, Y., Nakamura, M., Otsuka, M., Teramachi, H., Tsuchiya, T., et al. (2011). The pivotal role of intracellular calcium in oxaliplatin-induced inhibition of neurite outgrowth but not cell death in differentiated PC12 cells. Chem. Res. Toxicol. 24, 1845-1852. doi: 10.1021/tx200160g.
78. Thompson, S. W., Davis, L. E., Kornfeld, M., Hilgers, R. D., and Standefer, J. C. (1984). Cisplatin neuropathy. Clinical, electrophysiologic, morphologic, and toxicologic studies. Cancer 54, 1269-1275.
79. Tsai, C. Y., Larson, C. A., Safaei, R., and Howell, S. B. (2014). Molecular modulation of the copper and cisplatin transport function of CTR1 and its interaction with IRS-4. Biochem. Pharmacol. 90, 379-387. doi: 10.1016/j.bcp.2014.06.019.
80. Tzvetkov, M. V., Behrens, G., O'Brien, V. P., Hohloch, K., Brockmoller, J., and Benohr, P. (2011). Pharmacogenetic analyses of cisplatin-induced nephrotoxicity indicate a renoprotective effect of ERCC1 polymorphisms. Pharmacogenomics 12, 1417-1427. doi: 10.2217/pgs.11.93.
81. van den Berghe, P. V., Folmer, D. E., Malingre, H. E., van Beurden, E., Klomp, A. E., van de Sluis, B., et al. (2007). Human copper transporter 2 is localized in late endosomes and lysosomes and facilitates cellular copper uptake. Biochem. J. 407, 49-59. doi: 10.1042/BJ20070705.
82. Wang, D., and Lippard, S. J. (2005). Cellular processing of platinum anticancer drugs. Nat. Rev. Drug Discov. 4, 307-320. doi: 10.1038/nrd1691.
83. Wehe, C. A., Beyer, G., Sperling, M., Ciarimboli, G., and Karst, U. (2014). Assessing the intracellular concentration of platinum in medulloblastoma cell lines after Cisplatin incubation. J. Trace Elem. Med. Biol. 28, 166-172. doi: 10.1016/j.jtemb.2014.01.001.
84. Wen, X., Buckley, B., McCandlish, E., Goedken, M. J., Syed, S., Pelis, R., et al. (2014). Transgenic expression of the human MRP2 transporter reduces cisplatin accumulation and nephrotoxicity in Mrp2-null mice. Am. J. Pathol. 184, 1299-1308. doi: 10.1016/j.ajpath.2014.01.025.
85. Xu, X., Duan, L., Zhou, B., Ma, R., Zhou, H., and Liu, Z. Q. (2012). Genetic polymorphism of copper transporter protein 1 is related to platinum resistance in Chinese non-small cell lung carcinoma patients. Clin. Exp. Pharmacol. Physiol. 39, 786-792. doi: 10.1111/j.1440-1681.2012.05741.x.
86. Yang, J., Kalogerou, M., Gallacher, J., Sampson, J. R., and Shen, M. H. (2013). Renal tumours in a Tsc1+/-mouse model show epigenetic suppression of organic cation transporters Slc22a1, Slc22a2 and Slc22a3, and do not respond to metformin. Eur. J. Cancer 49, 1479-1490. doi: 10.1016/j.ejca.2012.10.027.
87. Yasumasu, T., Ueda, T., Uozumi, J., Mihara, Y., and Kumazawa, J. (1992). Comparative study of cisplatin and carboplatin on pharmacokinetics, nephrotoxicity and effect on renal nuclear DNA synthesis in rats. Pharmacol. Toxicol. 70, 143-147. doi: 10.1111/j.1600-0773.1992.tb00445.x.
88. Yokoo, S., Yonezawa, A., Masuda, S., Fukatsu, A., Katsura, T., and Inui, K. (2007). Differential contribution of organic cation transporters, OCT2 and MATE1, in platinum agent-induced nephrotoxicity. Biochem. Pharmacol. 74, 477-487. doi: 10.1016/j.bcp.2007.03.004.
89. Yonezawa, A., and Inui, K. (2011). Organic cation transporter OCT/SLC22A and H(+)/organic cation antiporter MATE/SLC47A are key molecules for nephrotoxicity of platinum agents. Biochem. Pharmacol. 81, 563-568. doi: 10.1016/j.bcp.2010.11.016.
90. Yonezawa, A., Masuda, S., Nishihara, K., Yano, I., Katsura, T., and Inui, K. (2005). Association between tubular toxicity of cisplatin and expression of organic cation transporter rOCT2 (Slc22a2) in the rat. Biochem. Pharmacol. 70, 1823-1831. doi: 10.1016/j.bcp.2005.09.020.
91. Yonezawa, A., Masuda, S., Yokoo, S., Katsura, T., and Inui, K. (2006). Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family). J. Pharmacol. Exp. Ther. 319, 879-886. doi: 10.1124/jpet.106.110346.
92. Yoshizawa, K., Nozaki, S., Kitahara, H., Ohara, T., Kato, K., Kawashiri, S., et al. (2007). Copper efflux transporter (ATP7B) contributes to the acquisition of cisplatin-resistance in human oral squamous cell lines. Oncol. Rep. 18, 987-991. doi: 10.3892/or.18.4.987.
93. Zhang, J., and Zhou, W. (2012). Ameliorative effects of SLC22A2 gene polymorphism 808 G/T and cimetidine on cisplatin-induced nephrotoxicity in Chinese cancer patients. Food Chem. Toxicol. 50, 2289-2293. doi: 10.1016/j.fct.2012.03.077.